Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

“Chronic kidney disease is a global healthcare problem ... largest private equity buyouts in Japan's health sector. Novo Nordisk's Ozempic has become the first drug in the GLP-1 class to be ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk A/S today announced 2024 earnings ... we can see a potential approval for semaglutide in T2D patients with chronic kidney disease (“CKD”) (the drug was in fact approved in ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

Danish drugmaker Novo Nordisk (NVO) reported fourth quarter ... Wegovy has been approved for cardiovascular benefits, and Ozempic for kidney disease. The approval for Wegovy opened the door ...